Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice-Reference-Cited by-同舟云学术

Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice

Published:2012-01-07 Issue:7 Volume:42 Page:702-708
ISSN:0014-2972
Container-title:European Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Alipour Arash,Valdivielso Pedro,Elte Jan Willem F.,Janssen Hans W.,Rioja Jose,van der Meulen Noëlle,van Mechelen Rob,Njo Tjin L.,González-Santos Pedro,Rietveld Arie P.,Cabezas Manuel Castro

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2362.2011.02635.x/fullpdf

Reference44 articles.

1. Atherogenesis: a postprandial phenomenon;Zilversmit;Circulation,1979

2. Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia;Gianturco;Semin Thromb Hemost,1988

3. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state;Patsch;Arterioscler Thromb,1992

4. Postprandial lipoproteins and progression of coronary atherosclerosis;Karpe;Atherosclerosis,1994

5. Fasting and daylong triglycerides in obesity with and without type 2 diabetes;van Wijk;Metabolism,2003

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of pulmonary rehabilitation on cardiovascular risk, oxidative stress and systemic inflammation in patients with COPD;Respiratory Medicine;2024-10

2. Subclinical atherosclerosis burden in non-diabetic hypertensives treated in primary care center: the IMTABI study;BMC Primary Care;2023-02-09

3. The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study);Frontiers in Cardiovascular Medicine;2023-01-25

4. Could the chylomicron marker apoB48 be of value in the diagnosis of chylous effusions?;Clinica Chimica Acta;2023-01

5. Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment;Clinical Chemistry and Laboratory Medicine (CCLM);2022-06-10